KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cvs Health (CVS) Shares Outstanding (Weighted Average) (2016 - 2025)

Cvs Health's Shares Outstanding (Weighted Average) history spans 17 years, with the latest figure at $1.3 billion for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 0.64% year-over-year to $1.3 billion, compared with a TTM value of $1.3 billion through Dec 2025, up 0.64%, and an annual FY2025 reading of $1.3 billion, up 0.64% over the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $1.3 billion at Cvs Health, roughly flat from $1.3 billion in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $1.3 billion in Q2 2021, with the low at $1.3 billion in Q2 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $1.3 billion, with a median of $1.3 billion recorded in 2023.
  • Year-over-year, Shares Outstanding (Weighted Average) grew 0.76% in 2021 and then decreased 2.28% in 2023.
  • Tracing CVS's Shares Outstanding (Weighted Average) over 5 years: stood at $1.3 billion in 2021, then decreased by 0.53% to $1.3 billion in 2022, then decreased by 2.06% to $1.3 billion in 2023, then dropped by 2.02% to $1.3 billion in 2024, then grew by 0.64% to $1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for CVS's Shares Outstanding (Weighted Average) are $1.3 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.3 billion (Q2 2025).